RxLibra

Search Generic Medicine

Medicine Index

Search by generic name

Generic Entrectinib

Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor.

Entrectinib is approved to treat:

  • Non-small cell lung cancer that is ROS1 positive(ROS1+NSCLC). It is used in adults whose cancer has metastasized (spread to other parts of the body).
  • Solid tumors that have an NTRK gene fusion without a drug-resistance mutation in certain TRK proteins. It is used in adults and in children aged 12 years or older whose cancer has metastasized or cannot be removed by surgery and has gotten worse after other treatment or cannot be treated with other therapies.

Entrectinib sold as brand names Rozlytrek,It has a generic form of several brands.


PHOENTRE Entrectinib

Brand Name : PHOENTRE
Composition : Entrectinib 100mg
Indication: Antineoplastic-Protein-Tyrosine Kinase Inhibitors
Form : Capsule (Oral administration)
Packing : 60 Capsules in 1 box
Manufactured By:PHARMACEUTICAL FACTORY NO.2(PHARMA 2 VIENTIANE)[Laos]
Storage:Store at room temperature (10-30°C)

Aentrek Entrectinib

Brand Name : Aentrek
Composition : Entrectinib 100mg&200mg
Indication: Antineoplastic-Protein-Tyrosine Kinase Inhibitors
Form : Capsule (Oral administration)
Packing : 100mg-30 Capsules & 200mg-90Capsules
Manufactured By:TONGMENG Pharmaceutical and Food Co., Ltd [Laos]
Storage:Store at room temperature (10-30°C)


Entrectinib dosing information

Usual Adult Dose for Non-Small Cell Lung Cancer:

  • 600 mg orally once a day until disease progression or unacceptable toxicity
  • Use: For adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive

Usual Adult Dose for Solid Tumors:

  • 600 mg orally once a day until disease progression or unacceptable toxicity
  • Uses: For adult patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity; and have progressed following treatment or have no satisfactory alternative therapy.

Usual Pediatric Dose for Solid Tumors:

12 years and older:

  • Body surface area (BSA) greater than 1.5 m2: 600 mg orally once a day
  • BSA 1.11 to 1.5 m2: 500 mg orally once a day
  • BSA 0.91 to 1.1 m2: 400 mg orally once a day

Use: For pediatric patients 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity; and have progressed following treatment or have no satisfactory alternative therapy.

Entrectinib Uses:

12 anticancer drugs for treatment Pancreatic Cancer

4 Targeted drugs for treatment ROS1+ lung cancer

Tags:  ,

You must be logged in to post a comment.